Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can patient records reveal who will respond to neuroendocrine tumor treatments?

NCT ID NCT05168631

Knowledge-focused Sponsor: Latin American Cooperative Oncology Group Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 28, 2026 · Last updated Aug 28, 2026

Summary

This study looks back at the medical records of 88 adults with neuroendocrine tumors that have spread or cannot be removed. Researchers will examine how different patient characteristics and treatments relate to overall survival and other outcomes. The goal is to identify factors that help predict how the disease will progress, which could guide future treatment decisions.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
This study could help doctors better predict how neuroendocrine tumors will behave, leading to more personalized treatment plans.
What could go wrong
Because this is a retrospective review of existing records, it can only show associations, not cause and effect. The findings may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

88 people

The number who actually took part.

Started

May 2020

Finished

Jun 2022

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients aged 18 years or older and with histologically confirmed neuroendocrine tumors; or metastatic or inoperable disease; or patients with clinical information about the therapies received, including exclusive palliative care.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients aged 18 years or older and with histologically confirmed neuroendocrine tumors; * Metastatic or inoperable disease; * Patients with clinical information about the therapies received, including exclusive palliative care. Exclusion Criteria: * Lack of data on survival outcomes and/or details on treatments received.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Carcinoma;endocrine are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neuroendocrine neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Carcinoma;endocrine Neuroendocrine tumors

Contacts and locations

Locations

  • Ensino E Terapia de Inovacao Clinica Amo - Etica

    Salvador, Estado de Bahia, Brazil

  • Fundacao Antonio Prudente - Ac Camargo Center

    São Paulo, São Paulo, Brazil

  • Hospital Moinhos de Vento

    Porto Alegre, Rio Grande do Sul, Brazil

  • Hospital de Gastroenterología Carlos Bonorino Udaondo

    Buenos Aires, Buenos Aires, Argentina

  • INCan - Instituto Nacional de Cancerología

    Mexico City, Mexico City, Mexico

  • Instituto Alexander Fleming

    Buenos Aires, Buenos Aires, Argentina

  • Instituto Nacional de Enfermedades Neoplàsicas

    Surquillo, Peru

  • Universidade Federal do Ceará/HOSPITAL UNIVERSITARIO WALTER CANTIDIO

    Fortaleza, Ceará, Brazil

More trials for these conditions

Other studies related to the condition(s) this trial covers.